Alnylam présentera de nouvelles analyses lors du congrès Heart Failure 2026, soulignant le profil clinique constant du vutrisiran dans l’ATTR-CM

Key Takeaway: Alnylam Pharmaceuticals will present new analyses at the Heart Failure Congress 2026, focusing on the consistent clinical profile of vutrisiran in ATTR-CM. This presentation aims to highlight the drug's performance and relevance in treating this condition. Further details about the analyses and their implications are expected during the congress.